以色列新藥可能成為阻止COVID-19大流行的關鍵
朱莉·斯塔爾（Julie Stahl）
CBN新聞
2021年2月12日
以色列特拉維夫-在初步試驗中取得成功的以色列藥物可能在抑制COVID-19大流行中起關鍵作用。 30名病情嚴重的患者參加了試驗，所有患者均康復，其中大多數患者在不到一周的時間內就康復了。
索尼婭·科恩（Sonya Cohen）是其中的一員，有朝一日她可以被看作是一個奇蹟。
她帶著COVID-19來到醫院，無法呼吸。她被接受了重症監護，需要氧氣。
那時特拉維夫Sourasky醫學中心預防醫學科負責人Nadir Arber教授來找她，問她是否將參與新藥的臨床試驗。索尼婭說是的。
索尼婭（Sonya）告訴CBN新聞：“從服用第一劑藥物開始，我感覺好多了。兩天后，我逐漸放下氧氣，可以呼吸了。” “我真的可以呼吸。我感到自己處於生與死之間。感謝上帝，當然也感謝醫生。”
CBN新聞最近在醫院，當時索尼婭帶著禮物回來了，親自對Arber博士表示感謝。
索尼婭（Sonya）告訴Arber：“我想對您所做的一切表示感謝。您救了我的命。我當時身體狀況很差，現在我好了。”
現在，研究人員渴望將這種療法用於批准的下一步。
Arber告訴CBN新聞：“這是一種藥物。非常簡單。我們將這種藥物給予患有嚴重疾病的患者，直到他們惡化為需要通氣甚至導致死亡的非常嚴重的疾病為止。”
阿爾伯（Arber）指導研發抗冠狀病毒藥物EXO-CD24，該藥物源自數十年前流產的兒童所建立的細胞系。
“我們在CD24上有很多經驗。我們也已經開始研究外泌體。外泌體[令人興奮。這是細胞彼此交談的方式。細胞與細胞之間的相互作用。這是令人驚奇的細胞。我們的身體互相交談，交流信息”，阿爾伯解釋說。
他說，對大多數人來說，COVID-19就像是普通流感。但是對於大約百分之五到百分之七的人來說，情況變得更糟。
他說：“我們並沒有真正對待電暈，而是對待了終點。” “免疫系統反應過度。免疫系統異常活躍，主要在肺部釋放大量細胞因子和趨化因子，通常與感染作鬥爭，但現在它們破壞了肺組織，非常脆弱”，阿爾伯說。
這就是他們干預和實施治療的要點，阿爾伯說，這中斷了這種細胞因子風暴。
他說：“我們通過吸入給藥。這很簡單。每天大約需要2-3分鐘，而您要進行5天。因此，我們在第一階段招募了30名患者。” “我們檢查了安全性，該藥物非常安全。沒有任何副作用。”
一期試驗的所有30名患者均康復。
根據Arber的說法，大多數患者在三到五天內就回家了。自從9月26日參與試驗的第一位患者以來，他們已經進行了將近150天的隨訪。他們發現這種藥物非常安全有效，而且沒有副作用。
儘管Arber認為接種疫苗很重要，但他也認為，如果在重要的人體試驗的其餘兩個階段都取得成功，則該藥可能會產生更大的影響。
他說：“當然，如果我的藥物有效，最大的優勢就是我可以快速，高效和廉價地生產它。在幾個月內，我就可以滿足全世界的需求。因此，這令人興奮。”
阿爾伯最近向總理本傑明·內塔尼亞胡介紹了治療進展。內塔尼亞胡說，如果EXO-CD24成功，結果將具有“全球意義”。
後來，在與來訪的希臘總理舉行的新聞發布會上，內塔尼亞胡稱讚了研究結果，並報告說希臘的醫院將參加臨床試驗。
內塔尼亞胡說：“如果您受到電暈感染，病情嚴重，並且有肺部疾病，可以服用，然後用鹽溶液吸入，然後出來，感覺很好。”包含藥品。
阿爾伯說，更多的國家希望參加，他相信這可能僅僅是開始。
“然後它將成為許多其他反應過度的疾病的平台，例如肺部和全身的自身免疫性疾病。
Extract:
*New Israeli Drug Could Hold a Key to Stopping the COVID-19 Pandemic*
*By Julie Stahl*
*CBN News*
*12 February 2021*
TEL AVIV, Israel - An Israeli drug that has been successful in initial trials, could hold a key in blunting the COVID-19 pandemic. Thirty patients in serious condition participated in the trial and all recovered, most of them in less than a week.
Sonya Cohen was one of them and she could one day be seen as a walking miracle.
Coming to the hospital with COVID-19, she was unable to breathe. She was placed in intensive care and needed oxygen.
That’s when Professor Nadir Arber, head of the Preventive Medicine Division at Tel Aviv’s Sourasky Medical Center, came to her and asked if she would be part of a clinical trial for a new drug. Sonya said yes.
"From the first [dose of the drug], it’s possible to say I felt a lot better. After two days I got off the oxygen in stages and I could breathe", Sonya told CBN News. "I could really breathe. I felt that I was between life and death. Thanks to God and of course thanks to the doctors."
CBN News was at the hospital recently when Sonya returned with gifts in hand to thank Dr Arber in person.
"I want to say thank you for everything. You saved my life. I was in a poor condition and now I’m better", Sonya told Arber.
Now researchers are eager to take the treatment on to the next steps toward approval.
"This is a drug. It is very simple. We give it to patients with severe disease before they are going to deteriorate to very severe disease that mandate[s] ventilations and even [leads to] mortality", Arber told CBN News.
Arber is directing the research on developing the anti-corona-virus drug, EXO-CD24, a treatment derived from a cell line established from a child aborted decades ago.
"We had a lot of experience on the CD24. We also had started to work on exosomes. Exosomes [are] something exciting. This is how a cell talks to each other. Cell-[to]-cell interaction. It’s amazing cells in our body speak to each other, exchange information", Arber explained.
He says for most people COVID-19 is like a regular flu. But for about five to seven percent of those who get it, it gets much worse.
"We don’t really treat the corona, we treated the endpoint", he said. "There [are] over-reactions of the immune system. The immune system is acting furiously and mainly in the lung releasing a lot of cytokines and chemokines that usually fight infections but now they are destroying the lung tissue, which is very friable", Arber said.
That’s the point they intervene and administer their treatment, which Arber says interrupts this cytokine storm.
"And we give it by inhalation. It’s very simple. It’s like 2-3 minutes per day and you do it for five days. So, we enrolled 30 patients in phase one", he said. "We checked for safety and the drug was very safe. No side effects whatsoever."
All 30 patients in that phase one trial recovered.
According to Arber, most of the patients went home in three to five days. Since the first patient in the trial was involved on September 26, they’ve had almost 150 days to follow-up. They have found the drug to be very safe and effective without side-effects.
While Arber believes the vaccination push is important, he also feels this drug could have an even bigger impact if the remaining two phases of important human trials are successful.
"The biggest advantage of my drug, if it’s effective of course, is that I can produce it fast, efficient, and cheap. Within a few months, I can supply the entire world’s needs. So, this is exciting", he said.
Arber recently briefed Prime Minister Benjamin Netanyahu on the treatment’s progress. Netanyahu said if the EXO-CD24 succeeds the results would have "global significance".
Later, at a press conference with the visiting Greek prime minister, Netanyahu praised the results and reported that Greek hospitals would join in the clinical trials.
"If you’re infected by corona and you’re seriously ill and you have a lung problem, you take this, you inhale this, with a saline solution and you come out, feeling good", Netanyahu said holding up the tiny bottle that contains the drug.
Arber says many more countries want to participate and he believes this could just be the beginning.
"And then it’s going to be the platform for many other disease[s], which overreact, like auto-immune disease in the lung[s] and in the entire body.
留住黃粱夢 Keep the Fantasy World 百歲光陰如夢蝶 留駐影音惜前緣: 以色列新藥可能成為阻止COVID-19大流行的關鍵 *New Israeli Drug Could... https://t.co/FoI7oHekKJ
— Chiunghsin Hsu (@johnsunhsu) February 22, 2021
沒有留言:
張貼留言